{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:09Z","timestamp":1792807209160,"version":"4.5.0"},"reference-count":70,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0011","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T08:31:06Z","timestamp":1679473866000},"source":"Crossref","is-referenced-by-count":46,"title":["Atopic dermatitis in children and adults"],"prefix":"10.3238","author":[{"given":"Andreas","family":"Wollenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Gieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"10.3238\/arztebl.m2023.0011_ref1","unstructured":"Zietze HA, Cabral C, Theobald K, et al.: [Epidemiology and treatment of adult patients with atopic dermatitis : analysis of longitudinal data of the statutory health insurance scheme]. Hautarzt 2021; 72: 963–74."},{"key":"10.3238\/arztebl.m2023.0011_ref2","doi-asserted-by":"crossref","unstructured":"Kage P, Zarnowski J, Simon JC, Treudler R: Atopic dermatitis and psychosocial comorbidities—What‘s new? Allergol Select 2020; 4: 86–96.","DOI":"10.5414\/ALX02174E"},{"key":"10.3238\/arztebl.m2023.0011_ref3","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et al.: ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717–44.","DOI":"10.1111\/jdv.16892"},{"key":"10.3238\/arztebl.m2023.0011_ref4","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Kinberger M, Arents B, et al.: European guideline (EuroGuiDerm) on atopic eczema: part I. J Eur Acad Dermatol Venereol 2022; 36: 1409–31.","DOI":"10.1111\/jdv.18345"},{"key":"10.3238\/arztebl.m2023.0011_ref5","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Kinberger M, Arents B, et al.: European guideline EuroGuiDerm) on atopic eczema—part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 2022; 36: 1904–26.","DOI":"10.1111\/jdv.18429"},{"key":"10.3238\/arztebl.m2023.0011_ref6","doi-asserted-by":"crossref","unstructured":"Ring J, Zink A, Arents BWM, et al.: Atopic eczema: burden of disease and individual suffering—results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331–40.","DOI":"10.1111\/jdv.15634"},{"key":"10.3238\/arztebl.m2023.0011_ref7","doi-asserted-by":"crossref","unstructured":"Suaini NHA, Tan CPT, Loo EXL, Tham EH: Global differences in atopic dermatitis. Pediatr Allergy Immunol 2021; 32: 23–33.","DOI":"10.1111\/pai.13335"},{"key":"10.3238\/arztebl.m2023.0011_ref8","doi-asserted-by":"crossref","unstructured":"Schmid-Grendelmeier P, Takaoka R, Ahogo KC, et al.: Position statement on atopic dermatitis in Sub-Saharan Africa: current status and roadmap. Eur Acad Dermatol Venereol 2019; 33: 2019–28.","DOI":"10.1111\/jdv.15972"},{"key":"10.3238\/arztebl.m2023.0011_ref9","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al.: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850–78."},{"key":"10.3238\/arztebl.m2023.0011_ref10","doi-asserted-by":"crossref","unstructured":"Gieler U, Schoof S, Gieler T, Scheewe S, Schut C, Kupfer J: Atopic eczema and stress among single parents and families: an empirical study of 96 mothers. Acta Derm Venereol 2017; 97: 42–6.","DOI":"10.2340\/00015555-2457"},{"key":"10.3238\/arztebl.m2023.0011_ref11","doi-asserted-by":"crossref","unstructured":"Eyerich S, Onken AT, Weidinger S, et al.: Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011; 365: 231–8.","DOI":"10.1056\/NEJMoa1104200"},{"key":"10.3238\/arztebl.m2023.0011_ref12","doi-asserted-by":"crossref","unstructured":"Kong HH, Oh J, Deming C, et al.: Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850–9.","DOI":"10.1101\/gr.131029.111"},{"key":"10.3238\/arztebl.m2023.0011_ref13","doi-asserted-by":"crossref","unstructured":"Schmid-Grendelmeier P, Scheynius A, Crameri R: The role of sensitization to Malassezia sympodialis in atopic eczema. Chem Immunol Allergy 2006; 91: 98–109.","DOI":"10.1159\/000090246"},{"key":"10.3238\/arztebl.m2023.0011_ref14","doi-asserted-by":"crossref","unstructured":"Alexander H, Paller AS, Traidl-Hoffmann C, et al.: The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol 2020; 182: 1331–42.","DOI":"10.1111\/bjd.18643"},{"key":"10.3238\/arztebl.m2023.0011_ref15","doi-asserted-by":"crossref","unstructured":"Wollenberg A: Eczema herpeticum. Chem Immunol Allergy 2012; 96: 89–95.","DOI":"10.1159\/000331892"},{"key":"10.3238\/arztebl.m2023.0011_ref16","doi-asserted-by":"crossref","unstructured":"Seegraber M, Worm M, Werfel T, et al.: Recurrent eczema herpeticum—a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol 2020; 34: 1074–9.","DOI":"10.1111\/jdv.16090"},{"key":"10.3238\/arztebl.m2023.0011_ref17","doi-asserted-by":"crossref","unstructured":"Neri I, Dondi A, Wollenberg A, et al.: Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol 2016; 33: 429–37.","DOI":"10.1111\/pde.12871"},{"key":"10.3238\/arztebl.m2023.0011_ref18","doi-asserted-by":"crossref","unstructured":"Langan SM, Irvine AD, Weidinger S: Atopic dermatitis. Lancet 2020; 396: 345–60.","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"10.3238\/arztebl.m2023.0011_ref19","doi-asserted-by":"crossref","unstructured":"Werfel T, Heratizadeh A, Aberer W, et al.: S2k guideline on diagnosis and treatment of atopic dermatitis—short version. J Dtsch Dermatol Ges 2016; 14: 92–106.","DOI":"10.1111\/ddg.12871"},{"key":"10.3238\/arztebl.m2023.0011_ref20","doi-asserted-by":"crossref","unstructured":"Traidl S, Lang C, Schmid-Grendelmeier P, Werfel T, Heratizadeh A: Comprehensive approach: current status on patient education in atopic dermatitis and other allergic diseases. Handb Exp Pharmacol 2022; 268: 487–500.","DOI":"10.1007\/164_2021_488"},{"key":"10.3238\/arztebl.m2023.0011_ref21","doi-asserted-by":"crossref","unstructured":"Buhl T, Beissert S, Gaffal E, et al.: COVID-19 and implications for dermatological and allergological diseases. J Dtsch Dermatol Ges 2020; 18: 815–24.","DOI":"10.1111\/ddg.14195"},{"key":"10.3238\/arztebl.m2023.0011_ref22","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al.: Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86: 357–78."},{"key":"10.3238\/arztebl.m2023.0011_ref23","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Frank R, Kroth J, Ruzicka T: Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7: 117–21.","DOI":"10.1111\/j.1610-0387.2008.06772.x"},{"key":"10.3238\/arztebl.m2023.0011_ref24","doi-asserted-by":"crossref","unstructured":"Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A: Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006–2011. J Eur Acad Dermatol Venereol 2015 29: 1071–81.","DOI":"10.1111\/jdv.12750"},{"key":"10.3238\/arztebl.m2023.0011_ref25","doi-asserted-by":"crossref","unstructured":"Siegels D, Heratizadeh A, Abraham S, et al.: Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy 2021; 76: 1053–76.","DOI":"10.1111\/all.14631"},{"key":"10.3238\/arztebl.m2023.0011_ref26","doi-asserted-by":"crossref","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al.: Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459–73.","DOI":"10.1111\/bjd.17869"},{"key":"10.3238\/arztebl.m2023.0011_ref27","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al.: Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437–49.","DOI":"10.1111\/bjd.19574"},{"key":"10.3238\/arztebl.m2023.0011_ref28","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Toth D, Bieber T, et al.: Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184: 450–63.","DOI":"10.1111\/bjd.19573"},{"key":"10.3238\/arztebl.m2023.0011_ref29","doi-asserted-by":"crossref","unstructured":"Simpson EL, Lacour JP, Spelman L, et al.: Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242–55.","DOI":"10.1111\/bjd.18898"},{"key":"10.3238\/arztebl.m2023.0011_ref30","doi-asserted-by":"crossref","unstructured":"Simpson EL, Sinclair R, Forman S, et al.: Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–66.","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"10.3238\/arztebl.m2023.0011_ref31","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al.: Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151–68.","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"10.3238\/arztebl.m2023.0011_ref32","doi-asserted-by":"crossref","unstructured":"Staab D, Diepgen TL, Fartasch M, et al.: Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933–8.","DOI":"10.1136\/bmj.332.7547.933"},{"key":"10.3238\/arztebl.m2023.0011_ref33","doi-asserted-by":"crossref","unstructured":"Heratizadeh A, Werfel T, Wollenberg A, et al.: Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol 2017; 140: 845–53 e3.","DOI":"10.1016\/j.jaci.2017.01.029"},{"key":"10.3238\/arztebl.m2023.0011_ref34","doi-asserted-by":"crossref","unstructured":"Ersser SJ, Cowdell F, Latter S, et al.: Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2014; CD004054.","DOI":"10.1002\/14651858.CD004054.pub3"},{"key":"10.3238\/arztebl.m2023.0011_ref35","unstructured":"Thamm R, Poethko-M\u00fcller C, H\u00fcther A, Thamm M: Allergische Erkrankungen bei Kindern und Jugendlichen in Deutschland—Querschnittergebnisse aus KiGGS Welle 2 und Trends. J Health Monit 2018; 3: 3–18."},{"key":"10.3238\/arztebl.m2023.0011_ref36","doi-asserted-by":"crossref","unstructured":"Siegels D, Haufe E, Heinrich L, et al.: Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274–86.","DOI":"10.5414\/ALX02262E"},{"key":"10.3238\/arztebl.m2023.0011_ref37","doi-asserted-by":"crossref","unstructured":"Flohr C, Mann J: New insights into the epidemiology of childhood atopic dermatitis. Allergy 2014; 69: 3–16.","DOI":"10.1111\/all.12270"},{"key":"10.3238\/arztebl.m2023.0011_ref38","doi-asserted-by":"crossref","unstructured":"Boehner A, Neuhauser R, Zink A, Ring J: Figurierte Erytheme—Aktueller Stand und diagnostisches Vorgehen. J Dtsch Dermatol Ges 2021; 19: 963–72.","DOI":"10.1111\/ddg.14450_g"},{"key":"10.3238\/arztebl.m2023.0011_ref39","doi-asserted-by":"crossref","unstructured":"Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl 1980; 92: 44–7.","DOI":"10.2340\/00015555924447"},{"key":"10.3238\/arztebl.m2023.0011_ref40","doi-asserted-by":"crossref","unstructured":"Williams HC, Burney PG, Pembroke AC, Hay RJ: The U.K. Working Party‘s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406–16.","DOI":"10.1111\/j.1365-2133.1994.tb08532.x"},{"key":"10.3238\/arztebl.m2023.0011_ref41","doi-asserted-by":"crossref","unstructured":"Romanos M, Gerlach M, Warnke A, Schmitt J: Association of attention-deficit\/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–73.","DOI":"10.1136\/jech.2009.093534"},{"key":"10.3238\/arztebl.m2023.0011_ref42","unstructured":"Schmitt J, Apfelbacher C, Heinrich J, Weidinger S, Romanos M: [Association of atopic eczema and attention-deficit\/hyperactivity disorder—meta-analysis of epidemiologic studies]. Z Kinder Jugendpsychiatr Psychother 2013; 41: 35–42; quiz –4."},{"key":"10.3238\/arztebl.m2023.0011_ref43","doi-asserted-by":"crossref","unstructured":"Bozek A, Jarzab J, Mielnik M, Bogacz A, Kozlowska R, Mangold D: Can atopy have a protective effect against cancer? PLoS One 2020; 15: e0226950.","DOI":"10.1371\/journal.pone.0226950"},{"key":"10.3238\/arztebl.m2023.0011_ref44","doi-asserted-by":"crossref","unstructured":"Srour J, Berg E, Mahltig B, Smolik T, Wollenberg A: Evaluation of antimicrobial textiles for atopic dermatitis. J Eur Acad Dermatol Venereol 2019; 33: 384–90.","DOI":"10.1111\/jdv.15123"},{"key":"10.3238\/arztebl.m2023.0011_ref45","doi-asserted-by":"crossref","unstructured":"Mayser P, Kupfer J, Nemetz D, et al.: Treatment of head and neck dermatitis with ciclopiroxolamine cream—results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19; 153–8.","DOI":"10.1159\/000092596"},{"key":"10.3238\/arztebl.m2023.0011_ref46","doi-asserted-by":"crossref","unstructured":"Paternoster L, Standl M, Waage J, et al.: Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet 2015; 47: 1449–56.","DOI":"10.1038\/ng.3424"},{"key":"10.3238\/arztebl.m2023.0011_ref47","doi-asserted-by":"crossref","unstructured":"Irvine AD, McLean WH, Leung DY: Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365: 1315–27.","DOI":"10.1056\/NEJMra1011040"},{"key":"10.3238\/arztebl.m2023.0011_ref48","doi-asserted-by":"crossref","unstructured":"Lee GR, Fields PE, Griffin TJ, Flavell RA: Regulation of the Th2 cytokine locus by a locus control region. Immunity 2003; 19: 145–53.","DOI":"10.1016\/S1074-7613(03)00179-1"},{"key":"10.3238\/arztebl.m2023.0011_ref49","doi-asserted-by":"crossref","unstructured":"Kretschmer A, M\u00f6ller G, Lee H, et al.: A common atopy-associated variant in the Th2 cytokine locus control region impacts transcriptional regulation and alters SMAD3 and SP1 binding. Allergy 2014; 69: 632–42.","DOI":"10.1111\/all.12394"},{"key":"10.3238\/arztebl.m2023.0011_ref50","doi-asserted-by":"crossref","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD: Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1.","DOI":"10.1038\/s41572-018-0001-z"},{"key":"10.3238\/arztebl.m2023.0011_ref51","doi-asserted-by":"crossref","unstructured":"Ott H: Guidance for assessment of erythroderma in neonates and infants for the pediatric immunologist. Pediatr Allergy Immunol 2019; 30: 259–68.","DOI":"10.1111\/pai.13032"},{"key":"10.3238\/arztebl.m2023.0011_ref52","doi-asserted-by":"crossref","unstructured":"Werfel T, Heratizadeh A, Niebuhr M, et al.: Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136: 96–103 e9.","DOI":"10.1016\/j.jaci.2015.04.015"},{"key":"10.3238\/arztebl.m2023.0011_ref53","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM: Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017; 2: CD012119.","DOI":"10.1002\/14651858.CD012119"},{"key":"10.3238\/arztebl.m2023.0011_ref54","doi-asserted-by":"crossref","unstructured":"\u00c5kerstr\u00f6m U, Reitamo S, Langeland T, et al.: Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol 2015; 95: 587–92.","DOI":"10.2340\/00015555-2051"},{"key":"10.3238\/arztebl.m2023.0011_ref55","doi-asserted-by":"crossref","unstructured":"Luger T, Loske KD, Elsner P, et al.: Topische Dermatotherapie mit Glukokortikoiden—Therapeutischer Index. J Dtsch Dermatol Ges 2004; 2: 629–34.","DOI":"10.1046\/j.1439-0353.2004.03626.x"},{"key":"10.3238\/arztebl.m2023.0011_ref56","doi-asserted-by":"crossref","unstructured":"Wir\u00e9n K, Frithiof H, Sjoqvist C, Loden M: Enhancement of bioavailability by lowering of fat content in topical formulations. Br J Dermatol 2009; 160: 552–6.","DOI":"10.1111\/j.1365-2133.2008.08981.x"},{"key":"10.3238\/arztebl.m2023.0011_ref57","doi-asserted-by":"crossref","unstructured":"Siegels D, Heratizadeh A, Abraham S, et al.: Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy 2021; 76: 1053–76.","DOI":"10.1111\/all.14631"},{"key":"10.3238\/arztebl.m2023.0011_ref58","doi-asserted-by":"crossref","unstructured":"Werfel T, Heratizadeh A, Aberer W, et al.: Update „systemic treatment of atopic dermatitis“ of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 2021; 19: 151–68.","DOI":"10.1111\/ddg.14371"},{"key":"10.3238\/arztebl.m2023.0011_ref59","doi-asserted-by":"crossref","unstructured":"Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W: Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract 2021; 9: 1053–65.","DOI":"10.1016\/j.jaip.2020.11.034"},{"key":"10.3238\/arztebl.m2023.0011_ref60","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Beck LA, de Bruin Weller M, et al.: Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol 2022; 186: 453–65.","DOI":"10.1111\/bjd.20810"},{"key":"10.3238\/arztebl.m2023.0011_ref61","doi-asserted-by":"crossref","unstructured":"Beck LA, Thaci D, Deleuran M, et al.: Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat 2022; 33: 1608–16.","DOI":"10.1080\/09546634.2020.1871463"},{"key":"10.3238\/arztebl.m2023.0011_ref62","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al.: Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020; 182: 1120–35.","DOI":"10.1111\/bjd.18434"},{"key":"10.3238\/arztebl.m2023.0011_ref63","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Paller AS: JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021; 148: 927–40.","DOI":"10.1016\/j.jaci.2021.08.009"},{"key":"10.3238\/arztebl.m2023.0011_ref64","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al.: Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047–55.","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"10.3238\/arztebl.m2023.0011_ref65","doi-asserted-by":"crossref","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al.: Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384: 1101–12.","DOI":"10.1056\/NEJMoa2019380"},{"key":"10.3238\/arztebl.m2023.0011_ref66","doi-asserted-by":"crossref","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ: Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol 2022; 61: 746–54.","DOI":"10.1111\/ijd.15853"},{"key":"10.3238\/arztebl.m2023.0011_ref67","doi-asserted-by":"crossref","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al.: Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44–56.","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"10.3238\/arztebl.m2023.0011_ref68","doi-asserted-by":"crossref","unstructured":"Paller AS, Siegfried EC, Thaci D, et al.: Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282–93.","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"10.3238\/arztebl.m2023.0011_ref69","doi-asserted-by":"crossref","unstructured":"Patel KR, Immaneni S, Singam V, Rastogi S, Silverberg JI: Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80; 402–10.","DOI":"10.1016\/j.jaad.2018.08.063"},{"key":"10.3238\/arztebl.m2023.0011_ref70","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte: Januskinase-Inhibitoren: Behandlung von Entz\u00fcndungskrankheiten. www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/g-l\/januskinase.html (last accessed on 9 January 2023)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T08:33:15Z","timestamp":1679473995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":70,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0011","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}